126070-20-0

Basic information

• Product Name: 4-(((Tert-Butyldimethylsilyl)Oxy)Methyl)Phenol
• Synonyms: 4-(((Tert-Butyldimethylsilyl)Oxy)Methyl)Phenol;Phenol, 4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-;4-(((tert-butyldimethylsilyl)oxy)methyl)phenol(WXC04509)
• CAS NO: 126070-20-0
• Molecular Formula: C₁₃H₂₂O₂Si
• Molecular Weight: 238.39808
• Mol File: 126070-20-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(((Tert-Butyldimethylsilyl)Oxy)Methyl)Phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(((Tert-Butyldimethylsilyl)Oxy)Methyl)Phenol(126070-20-0)
• EPA Substance Registry System: 4-(((Tert-Butyldimethylsilyl)Oxy)Methyl)Phenol(126070-20-0)

Safety Data

• Hazardous Substances Data: 126070-20-0(Hazardous Substances Data)

Upstream product

• 117635-46-8 1-(tert-butyldimethylsilyloxy)-4-((tert-butyldimethylsilyloxy)methyl)benzene 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 288-32-4 1H-imidazole 
• 1058019-24-1 C₁₆H₂₄O₂Si 
• 1114567-57-5 C₂₉H₄₀O₂Si₂ 
• 1198597-47-5 C₂₂H₄₂O₂Si₂ 
• 1228447-97-9 tert-butyl(4-(iso-propoxydimethylsilyl)benzyloxy)dimethylsilane 
• 1393446-12-2 tert-butyl((4-(dimethylsilyl)benzyl)oxy)dimethylsilane 
• 87736-74-1 4-(tert-butyldimethylsiloxymethyl)bromobenzene 

Downstream Products

• 70362-64-0 4-(hydroxymethyl)phenyl isobutyrate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 945629-89-0 2-[4-(tert-butyldimethylsiloxymethyl)phenoxymethyl]-5-methoxy-1,3-dimethylindole-4,7-dione 
• 945629-92-5 3-[4-(tert-butyldimethylsiloxymethyl)phenoxymethyl]-5-methoxy-1,2-dimethylindole-4,7-dione 
• 945629-90-3 2-[(4-hydroxymethyl)phenoxy]methyl-5-methoxy-1,3-dimethylindole-4,7-dione 
• 945629-93-6 3-[(4-hydroxymethyl)phenoxy]methyl-5-methoxy-1,2-dimethylindole-4,7-dione 
• 945630-01-3 (5-methoxy-1,2-dimethyl-4,7-dioxoindol-3-yl)methyloxyphenyl-4-phenyl carbonate 
• 182878-05-3 4-(isopropylcarbonyl-oxy)benzyl iodide 
• 658053-71-5 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-butanoic acid 4-tert-butyldimethylsilanyloxymethyl-phenyl ester 
• 899799-91-8 (S)-3-(4-((tert-butyldimethylsilyloxy)methyl)phenoxy)-dihydrofuran-2(3H)-one 
• 848004-48-8 C₂₅H₃₇NO₇Si 
• 1202249-33-9 4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl (4-nitrophenyl)carbonate 

Relevant articles and documents

Photochemical Amplifier Based on Self-Immolative Dendritic Spacers

A self-immolative dendritic structure was synthesized. It is based on phenol derivatives with three hydroxymethyl arms at both ortho and para positions of the core unit, potentially releasing up to 27 leaving groups in a third-generation dendrimer. The tr

Selective deprotection of silyl-protected phenols using solid NaOH and a phase transfer catalyst

Aryl silyl ethers can be deprotected to yield phenols in good to excellent yields using a biphasic system of 10 equivalents of NaOH and catalytic Bu4NHSO4 in 1,4-dioxane. Alkyl silyl ethers prepared using a variety of silyl protecting groups survive under these conditions, allowing selective deprotection of silyl-protected phenols in the presence of silyl- protected alcohols.

COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF

Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a -S(=0)(=N-)- functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Fluorescent probe for detecting cysteine

The invention discloses a fluorescent probe for detecting cysteine. According to the invention, the fluorescent probe can identify and distinguish cysteine from various amino acids and some common substances; when the probe acts with Cys, the fluorescence

COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF

The present invention relates to a cleavable linker platform. In particular, the invention relates to construction of an enzyme cleavable linker platform conjugated to a drug or a diagnostically relevant compound, a biomolecule, and an enzyme cleavable group, for which cleavage of the enzyme cleavable group leads to release of the drug or diagnostically relevant compound.

DOUBLE-HEADED PROTEASE INHIBITOR

The present invention provides a compound that is highly safe and useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical composition containing the compo

ANTICANCER AGENT DELIVERY MOLECULE

PROBLEM TO BE SOLVED: To provide a compound which can be used as an anticancer agent targeting a cancer cell that highly expresses Lysine-specific demethylase 1 (LSD1) or salt thereof. SOLUTION: The present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, where Ar, R1, R2, L, Z, p, q, *1 and *2 are as defined in the specifications. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

LYMPH DIRECTING PRODRUGS

H:\dar\Interwoven\NRPortbl\DCC\DAR\8230712_1.doc-12/08/2015 Abstract The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

Conformational Constraint of the Glycerol Moiety of Lysophosphatidylserine Affords Compounds with Receptor Subtype Selectivity

Lysophosphatidylserine (LysoPS) is an endogenous lipid mediator that specifically activates membrane proteins of the P2Y and its related families of G protein-coupled receptors (GPCR), GPR34 (LPS1), P2Y10 (LPS2), and GPR174 (LPS3). Here, in order to increase potency and receptor selectivity, we designed and synthesized LysoPS analogues containing the conformational constraints of the glycerol moiety. These reduced structural flexibility by fixation of the glycerol framework of LysoPS using a 2-hydroxymethyl-3-hydroxytetrahydropyran skeleton, and related structures identified compounds which exhibited high potency and selectivity for activation of GPR34 or P2Y10. Morphing of the structural shape of the 2-hydroxymethyl-3-hydroxytetrahydropyran skeleton into a planar benzene ring enhanced the P2Y10 activation potentcy rather than the GPR34 activation.

LYSOPHOSPHATIDYLSERINE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a lysophosphatidylserine derivative or salt thereof. SOLUTION: The present invention provides a lysophosphatidylserine derivative or salt thereof, or a pharmaceutical composition or lysophosphatidylserine receptor function modulator including the compound or salt thereof. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT